SCHEMBL1320693

SCHEMBL1320693

Cc1ccc(I)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPRA P18433 1/20 0.50
PTPRB P23467 1/20 0.50
PTPRE P23469 1/20 0.50
PTPN6 P29350 1/20 0.50
IDO1 P14902 2/20 0.45
MCL1 Q07820 1/20 0.43
TPMT P51580 1/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 3/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CSNK2A1 P68400 1/20 0.41
NOTUM Q6P988 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28904215 0.84 PTPRC (0.39) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL7715 0.83 IDO1 (0.49) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL30748562 0.83 IDO1 (0.49) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL12806404 0.81 PTPRC (0.37) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL522679 0.79 PTPN1 (0.55) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL12671441 0.79 PTGS2 (0.51) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL17307119 0.78 PTPRC (0.34) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL7903905 0.78 MAP2K2 (0.41) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL12240241 0.78 CA12 (0.43) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL223101 0.77 CSNK2A1 (0.65) MCL1ALDH1A1KDM4EHPGDCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113683593-B Preparation method of canagliflozin intermediate and application of canagliflozin intermediate in preparation of canagliflozin 湖北石河医药科技有限公司 2023-11-17 CN claimed
CN-113683593-A Preparation method of canagliflozin intermediate and application of canagliflozin intermediate in preparation of canagliflozin 湖北石河医药科技有限公司 2021-11-23 CN claimed
CN-213000621-U 5-iodine-2-methyl benzoic acid centrifugal device 江苏恒洲化工有限公司 2021-04-20 CN claimed
CN-213020600-U 5-iodine-2-methyl benzoic acid drying device 江苏恒洲化工有限公司 2021-04-20 CN claimed
CN-210906154-U Reaction unit is used in production of 5-iodine-2-methyl benzoic acid 江苏恒洲化工有限公司 2020-07-03 CN claimed
EP-3059220-B1 METHOD OF PREPARING AND RECOVERING 2-METHYL-5-IODOBENZOIC ACID ABA CHEMICALS CORP (CN) 2018-12-05 EP claimed
CN-107652175-A A kind of synthetic method of the iodo-benzoic acid of 2 methyl 5 宁波人健化学制药有限公司 2018-02-02 CN claimed
EP-3059220-A1 METHOD OF PREPARING AND RECOVERING 2-METHYL-5-IODOBENZOIC ACID ABA Chemicals Corporation (CN) 2016-08-24 EP claimed
CN-103539662-B Preparation and recovery method of 2-methyl-5-iodobenzoic acid ABA CHEMICALS CORP 2015-04-08 CN claimed
CN-103539662-A Preparation and recovery method of 2-methyl-5-iodobenzoic acid ABA CHEMICALS CORP 2014-01-29 CN claimed
EP-1595862-B1 PROCESS FOR PRODUCTION OF IODINE COMPOUNDS AND PROCESS FOR PRODUCTION OF HIGH-PURITY 5-IODO-2-METHYLBENZOIC ACID MITSUBISHI GAS CHEMICAL CO (JP) 2010-11-17 EP claimed
EP-1642881-B1 PROCESS FOR PRODUCING 5-IODO-2-METHYLBENZOIC ACID MITSUBISHI GAS CHEMICAL CO (JP) 2010-10-27 EP claimed
US-7750182-B2 Process for production of iodine compounds and process for production of high-purity 5-iodo-2-methylbenzoic acid MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2010-07-06 US claimed
US-7642374-B2 Process for producing 5-iodo-2-methylbenzoic acid MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2010-01-05 US claimed
US-20060167312-A1 Process for producing 5-iodo-2-methylbenzoic acid MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2006-07-27 US claimed
US-20060161028-A1 Process for production of iodine compounds and process for production of high-purity 5-iodo-2-methylbenzoic acid MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2006-07-20 US claimed
EP-1642881-A1 PROCESS FOR PRODUCING 5-IODO-2-METHYLBENZOIC ACID MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2006-04-05 EP claimed
EP-1595862-A1 PROCESS FOR PRODUCTION OF IODINE COMPOUNDS AND PROCESS FOR PRODUCTION OF HIGH-PURITY 5-IODO-2-METHYLBENZOIC ACID MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2005-11-16 EP claimed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG PTPRC 209/4885PTPN2 196/4885PTPN1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.